Prof. Dr. med. Martin F. Fey

Prof. Martin Fey

Head of Department of Medical Oncology

University of Bern and Inselspital, CH-3010 Bern

Email: martin(.)fey(at)insel(.)ch

Phone: + 41 31 632 22 43

Fax: + 41 31 632 41 20

Group's Homepage:


Activities and Research Interests

Haematological oncology (both experimental and clinical )

Methodology of clinical trials in cancer medicine

Breast cancer clinical trials

Selected publications

  1. Nagel S., Borisch B., Thein S.L., Oestreicher M., Nöthiger F., Birrer S., Tobler A., Fey M.F.: So­matic mutations detected by mini- and microsatellite DNA mar­kers reveal clonal intra-tu­mour heterogeneity in gastrointestinal cancers. Cancer Research 1995; 55: 2866-2870
  2. Hasse U., Tinguely M., Oppliger Leibundgut E., Cajot J.F., Garvin A.M., Tobler A., Borisch B., Fey M.F.: Clonal loss of heterozygosity in Hodgkin/Reed-Sternberg cells. Journal of the Na­tional Cancer Institute 1999; 91: 1581-1583
  3. Mengis C., Aebi S., Tobler A., Dähler W., Fey M.F.: Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelo-genous leukaemia trials. Journal of Clinical Oncology 2003; 21: 3933-3939
  4. Löwenberg B., van Putten W., Theobald M., Gmür J., Verdonck L., Sonneveld P., Fey M.F., Schouten H., de Greef G., Ferrant A., Kovascovics T., Gratwohl A., Daenen S., Huijgens P., Boogaerts M., Dutch-Belgian Hemato-Oncology Cooperative Group, Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukaemia. New England Journal of Medicine 2003; 349: 743-752
  5. Wick C., Egger M., Trelle S., Jüni P., Fey M.F.: The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry. Annals of Oncology 2007; 18: 1580-1582
  6. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., Zwahlen M., Clarke M., Weingart O., Kluge S., Piper M., Rades D., Steensma D.P., Djulbegovic B.; Fey M.F., Ray-Coquard I., Machtay M., Moebus V., Thomas G., Untch M., Schumacher M., Egger M., Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in cancer patients: patient-level meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542
  7. Vellenga E., van Putten W., Ossenkoppele G.J., Verdonck L.F., Theobald M., Cornelissen J.J., Huijgens P.C., Maertens J., Gratwohl A., Schaafsma R., Schanz U., Graux C., Schouten H.C., Ferrant A., Bargetzi M., Fey M.F., Löwenberg B. Autologous peripheral blood stem cell transplantation for acute myeloid leukaemia. Blood 2011; 118: 6037-6042
  8.  Humbert M., Federzoni E.A., Britschgi A., Schläfli A.M., Valk P.J., Kaufmann T., Haferlach T., Behre G., Simon H.U., Torbett B.E., Fey M.F., Tschan M.P. The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL. Journal of Leukocyte Biology 2014; 95: 83-93
  9. Fey M.F.: Molecular biology of cancer. In: Cavalli F., Kaye S.B., Hansen H.H., Armitage J.O., Piccart-Gebhart M.J. (Eds.) “ESMO Textbok of Medical Oncology” 4th edition 2009; 1-26. Informa UK Ltd,  London UK
  10. O’Sullivan B, Brierley, J., Pollock R., d’Cruz A., Fey M.F., Vermorken J. Ed. UICC Manual of Clinical Oncology. Wiley Blackwell (2015)